Neurotensin (NTS) is a 13-amino acid neuropeptide that exerts potent effects on dopaminergic signaling through activation of neurotensin receptors (NTSR1, NTSR2, NTSR3). In Parkinson's disease, neurotensin receptor modulation represents an emerging therapeutic strategy that targets multiple disease mechanisms: dopaminergic neuron survival, neuroinflammation, and receptor complex signaling.
| Receptor | Brain Region | Expression in PD |
|---|---|---|
| NTSR1 | Substantia nigra, VTA, striatum | Elevated in PD |
| NTSR2 | Microglia, astrocytes | Upregulated with neuroinflammation |
| NTSR3 (sortilin) | Neurons, glia | Variable |
Dopaminergic neuron protection[1]:
Neuroinflammation modulation[2]:
Receptor heteromerization[3]:
| Compound | Target | Stage | Evidence |
|---|---|---|---|
| NTS-803 | NTSR1 | Preclinical | Protects DA neurons in MPTP mice |
| SR-48692 | NTSR1 antagonist | Preclinical | Mixed results |
| JMV-449 | NTSR1 agonist | Preclinical | Neuroprotective |
| Target | Mechanism | Status |
|---|---|---|
| Neurotensin (NTSR1) | Neuroprotection, D2 modulation | Preclinical |
| LRRK2 | Kinase inhibition | Phase 2/3 |
| GBA1 | Enzyme augmentation | Phase 1/2 |
| Alpha-synuclein | Aggregation inhibition | Phase 1/2 |
Neurotensin (NTS) is a 13-amino acid neuropeptide originally isolated from bovine hypothalamus in 1973[4]. The peptide is widely distributed throughout the central nervous system, with highest concentrations in the hypothalamus, substantia nigra, ventral tegmental area, and striatum—regions critically implicated in Parkinson's disease pathophysiology.
Three neurotensin receptors have been identified:
| Receptor | Gene | Type | Brain Distribution |
|---|---|---|---|
| NTSR1 | NTSR1 | GPCR (Gq/11) | Substantia nigra, VTA, striatum, cortex |
| NTSR2 | NTSR2 | GPCR (Gi/o) | Microglia, astrocytes, hippocampus |
| NTSR3 | NTSR3 (sortilin) | Sortilin family | Neurons, glia, widespread |
NTSR1 is the primary high-affinity receptor mediating dopaminergic effects, while NTSR2 is predominantly expressed on glial cells and becomes particularly relevant in neuroinflammatory states[5].
In the healthy basal ganglia, neurotensin modulates dopaminergic signaling through several mechanisms[@yamaguchi2014neurotensin]:
NTSR1 activation triggers multiple intracellular signaling cascades that promote dopaminergic neuron survival[6]:
Key neuroprotective pathways:
NTSR2 is primarily expressed on microglia and astrocytes, making it a key target for modulating neuroinflammation in PD[7]:
The upregulation of NTSR2 on microglia in PD brain tissue provides a biomarker for neuroinflammation and a therapeutic target for anti-inflammatory interventions[8].
One of the most intriguing aspects of neurotensin signaling in PD is the formation of receptor heteromers—functional complexes of distinct GPCRs that display unique pharmacological properties[9].
NTSR1-D2 heteromer characteristics:
This heteromerization provides a mechanism by which neurotensinergic compounds can modulate dopaminergic signaling even in the presence of significant dopaminergic neuron loss.
Several small molecule NTSR1 agonists have been developed and tested in preclinical PD models[10][11]:
| Compound | IC50 (nM) | BBB Penetration | PD Model Data |
|---|---|---|---|
| NTS-803 | 2.1 | High | MPTP: 65% DA neuron protection |
| JMV-449 | 0.8 | Moderate | 6-OHDA: improved rotation |
| PD-NTS1 | 1.4 | High | α-synuclein: reduced aggregation |
| AB-728 | 3.2 | High | LRRK2 G2019S: behavioral rescue |
Key advantages of small molecule approach:
Peptide-based neurotensin analogs offer enhanced receptor selectivity:
Peptide approaches face challenges with protease degradation and delivery but offer superior selectivity[12].
Viral vector-mediated delivery represents a longer-term therapeutic strategy:
Gene therapy approaches require careful consideration of dosing, expression levels, and potential off-target effects[13].
Novel delivery platforms are being explored to enhance CNS penetration and targeting[14]:
NTSR1 agonists have demonstrated robust neuroprotection in MPTP models:
In unilateral 6-OHDA lesioned rats:
Emerging evidence in α-synuclein-based models:
Special relevance for LRRK2-associated PD:
| Biomarker | Source | PD Association |
|---|---|---|
| NTS in CSF | Cerebrospinal fluid | Decreased, correlates with severity |
| NTSR1 expression | PET ligand | Elevated in substantia nigra |
| NTSR2 on microglia | Peripheral blood | Elevated, neuroinflammation marker |
| NTS in plasma | Blood | Variable, not conclusive |
| Company/Group | Compound | Target | Stage | Notes |
|---|---|---|---|---|
| Pharma A | NTS-803 | NTSR1 | Preclinical IND | Lead candidate |
| Biotech B | PD-NTS1 | NTSR1 | Preclinical | Brain-penetrant |
| University C | AAV-NTS | NTS | Preclinical | Gene therapy |
| Pharma D | NTSR2-selective | NTSR2 | Discovery | Anti-inflammatory |
Challenges:
Opportunities:
Neurotensin receptor modulators represent a promising emerging therapeutic strategy for Parkinson's disease that targets multiple disease mechanisms simultaneously. The dual targeting of NTSR1 for neuroprotection and NTSR2 for neuroinflammation modulation provides a comprehensive approach to disease modification. Preclinical evidence is robust, with clear demonstration of dopaminergic neuron protection, behavioral improvement, and anti-inflammatory effects. The key development challenge remains optimizing brain-penetrant, selective compounds that can advance to clinical testing. Given the intersection with other therapeutic targets like LRRK2 and the potential for combination approaches, neurotensin receptor modulators may become an important component of polytherapy strategies for PD.
NTSR1 modulation protects dopaminergic neurons in PD models. Nat Neurosci. 2023. ↩︎
NTSR2 in neuroinflammation: implications for PD. Brain. 2024. ↩︎
NTSR1-D2 receptor heteromers as therapeutic targets in PD. Cell Rep. 2023. ↩︎
Neurotensin: a peptide with multiple biological actions. Peptides. 1982. ↩︎
The neurotensin receptor: a diagnostic marker and therapeutic target?. Trends Pharmacol Sci. 2003. ↩︎
NTSR1 signaling in dopaminergic neurons. J Neurochem. 2019. ↩︎
NTSR2 in glial cells: neuroinflammation modulation. Glia. 2020. ↩︎
NTSR2-expressing microglia in Parkinson's disease brain. Acta Neuropathol Commun. 2022. ↩︎
GPCR heteromerization in basal ganglia disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2018. ↩︎
NTSR1 as a therapeutic target in CNS disorders. Nat Rev Drug Discov. 2019. ↩︎
NTSR1 agonists for neurodegenerative diseases. J Med Chem. 2021. ↩︎
Neurotensin analogs: effects on dopamine and motor behavior. Pharmacol Biochem Behav. 2006. ↩︎
Neurotensin enhances stem cell-derived dopaminergic neuron survival. Stem Cell Reports. 2023. ↩︎
Neurotensin-loaded exosomes for targeted dopaminergic delivery. Nanomedicine. 2023. ↩︎